Liver Fibrosis in Patients Transplanted for Hepatitis C Receiving Either Cyclosporine Microemulsion or Tacrolimus

Hepatitis C Clinical Trial

Official title:

A Multicenter, Randomized, Open-label Study to Compare the Development of Liver Fibrosis at 12 Months After Transplantation for Hepatitis C Cirrhosis in Patients Receiving Either Cyclosporine Microemulsion or Tacrolimus

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00260208
• Other study ID #: COLO400A2426
• Status: Terminated
• Phase: Phase 4
• First received: November 30, 2005
• Last updated: December 2, 2011
• Start date: January 2006

Study information

• Verified date: December 2011
• Source: Novartis
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

Following a transplant for hepatitis C cirrhosis, the infection comes back in 70-90% of cases and over time causes fibrosis and eventually cirrhosis of the new liver. The aim of this study was to see if the frequency of liver fibrosis was different with cyclosporine microemulsion than tacrolimus

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 361
• Est. primary completion date: September 2010
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion criteria

• Reason for transplant is end-stage liver disease due to hepatitis C cirrhosis

• Patients receiving a first liver transplant from a deceased or living donor

• Patients in whom biopsies will be possible

Exclusion criteria

• Recipients of a liver from an hepatitis C virus positive (HCV+), human immunodeficiency virus positive (HIV+) or hepatitis B virus positive (HBV+) donor

• Patients with any severe coexisting disease or suffering any unstable medical condition or co-infected with HBV or HIV

• Patients with co-existing alcoholic disease who have not been abstinent for at least 6 months

• Transplanted for liver cancer exceeding a pre-defined size

• Pregnant or nursing women

Other protocol-defined inclusion/exclusion criteria may apply

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis C
• Liver Transplant

Intervention

Drug:
• Cyclosporine A
Initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v.) within the first 24 hours post-transplantation.
• Tacrolimus
Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses either orally or via a nasogastric (NG) tube or intravenously (i.v).

Locations

Country	Name	City	State
Switzerland	Novartis Investigational Site	Zurich
United States	Novartis Investigative Site	East Hanover	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) = 2] Within 1 Year Post-transplant	Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis. Logistic regression on the presence of IK>=2 was applied based on central biopsy readings only.	1 year post-transplant	No
Secondary	Number of Participants With Combined Endpoint of Death or Graft Loss or Fibrosis Score (FS) = 2	The number of participants with combined end point of death or graft loss or presented with a Ishak-Knodell fibrosis score (FS) =2 was calculated. Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had liver retransplant or died. Assessment of hepatic fibrosis was performed with liver biopsies read centrally. Ishak-Knodell FS was used to stage liver disease; 0=none; 1=portal fibrosis (some); 2=portal fibrosis (most); 3=bridging fibrosis (few); 4=bridging fibrosis (many); 5=Incomplete cirrhosis; 6=cirrhosis. Higher score indicates greater fibrosis.	1 year post-transplant	Yes
Secondary	Number of Participants With Fibrosing Cholestatic Hepatitis	Fibrosing cholestatic hepatitis (FCH) is characterized by progressive jaundice with a rapid decline in liver function leading to liver failure, most often associated with markedly elevated viral levels detected in the bloodstream (e.g. more than 20 times pre-liver transplantation levels) and in the liver tissue as well. The presence of FCH was reported based on the diagnosis given by the investigator.	1 year post-transplantation	No
Secondary	Number of Participants With Death, Graft Loss, Death or Graft Loss, Graft Loss With Re-transplantation	Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had a liver re-transplant or died.	1 year post-transplant	Yes
Secondary	Number of Participants With Treated Acute Rejection, Biopsy Proven Acute Rejection (BPAR), and Sub-clinical Rejection	Treated acute rejection is defined as an acute rejection, clinically suspected, whether biopsy-proven or not, which has been treated and confirmed by the investigator according to the response to therapy. BPAR was defined as a treated acute rejection confirmed by biopsy. The local pathologist graded biopsies according to the Banff (1997) criteria. A sub-clinical rejection was defined as a rejection identified by center driven biopsy, i.e. a biopsy performed routinely at some pre-defined time points after transplantation as per center practice in the absence of any clinical signs of rejection.	1 year post-transplant	Yes
Secondary	Number of Participants With Combined Endpoint of Death or Graft Loss or Biopsy Proven Acute Rejection (BPAR)	BPAR was defined as a treated acute rejection confirmed by biopsy. The local pathologist graded biopsies according to the Banff (1997) criteria. Graft loss was considered to have occurred when allograft was presumed to be lost if a patient had a liver re-transplant or died.	1 year post-transplant	Yes
Secondary	Number of Participants With Death or Re-transplantation Due to Recurrence of Hepatitis C Cirrhosis	Cirrhosis was resulted due to the recurrence of the hepatitis C virus infection in the transplanted liver.	1 year post-transplant	Yes
Secondary	Number of Participants With Fibrosis Score 2 or Above [Ishak-Knodell Fibrosis Score (FS) = 2] Within 1 Year Post-transplant (Intent to Treat Population)	Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis.	1 year post-transplant	No
Secondary	Mean Value of Liver Function Tests at 1 Year Post-transplantation	The mean value (in Units per liter, IU/L) of following tests were calculated at 1 year post-transplant: Serum glutamic pyruvic transaminase (SGPT); Serum Glutamic Oxaloacetic Transaminase (SGOT); Bilirubin; Alkaline Phosphate; ?-Glutamyltransferase (GGT)	1 year post-transplant	No
Secondary	Log-transformed Hepatitis C Virus Ribonucleic Acid (HCV RNA) Values up to 1 Year Post Transplant	HCV RNA was measured (IU/µL)centrally pre-transplant (Day 1) and at 48 hours (Day 3), Day 8 and 29, Month 6 and 12 post-transplant and concomitantly to any additional biopsies performed.	Pre-transplant (Day 1), Day , Day 8, Day 29, Month 6 and 12 post- transplant	No
Secondary	Percentage of Participants With an Increase of at Least 1 Stage in Fibrosis	Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis. An increase of at least 1 stage demonstrated a worsening of the disease, i.e. the transition from one score to the next higher one.	Between 1 and 2 years	No
Secondary	Mean Fibrosis Score	Assessment of hepatic fibrosis was performed with liver biopsies at Day 1, Month 6, 12 and 24, read centrally by two independent pathologists blinded to treatment arm and time of biopsy. Ishak-Knodell score was used to stage liver disease; 0= None; 1= Portal fibrosis (some); 2= Portal fibrosis (most); 3= Bridging fibrosis (few); 4= Bridging fibrosis (many); 5 = Incomplete cirrhosis; 6 = Cirrhosis. Higher score indicates greater fibrosis. The mean score was equivalent to mean of IK at 1 and 2 years (evolution over time).	At 1and 2 years and its evolution over time	No